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Objectives The purpose of this study was to investigate the effects of increasing dose of intracoro-
nary adenosine on fractional ﬂow reserve (FFR) measurement.
Backgrounds FFR is a validated method for the assessment of the severity of coronary artery steno-
sis. It is based on the change in the pressure gradient across the stenosis after the achievement of
maximal hyperemia of the coronary microcirculation that may be obtained by either intracoronary
bolus or intravenous infusion of adenosine. No study has explored so far the effects of very high
doses of intracoronary adenosine on FFR.
Methods FFR was assessed in 46 patients with 50 intermediate lesions during cardiac catheteriza-
tion by pressure-recording guidewire (PrimeWire, Volcano, San Diego, California). FFR was calculated
as the ratio of the distal coronary pressure to the aortic pressure at hyperemia. Increasing doses of
adenosine were administrated (60, 120, 180, 360, and 720 g) as intracoronary boluses. Exclusion
criteria were: 1) allergy to adenosine; 2) baseline bradycardia (heart rate 50 beats/min); 3) hypo-
tension (blood pressure 90 mm Hg); and 4) refusal to provide signed informed consent.
Results High doses of intracoronary adenosine were well tolerated, with no major side effects. In-
creasing doses up to 720 g progressively decreased FFR values and increased the percentage of
patients showing an FFR 0.75. Among angiographic parameters, both percent stenosis and lesion
length were independently associated with lower FFR values.
Conclusions This study shows that high doses of intracoronary adenosine (up to 720 g) increased
the sensitivity of FFR in the detection of hemodynamically relevant coronary stenoses. Furthermore,
lesion length and stenosis severity were independent angiographic determinants of FFR.
(J Am Coll Cardiol Intv 2011;4:1079–84) © 2011 by the American College of Cardiology Foundation
From the Division of Cardiology, Ospedale “Maggiore della Carità,” Eastern Piedmont University, Novara, Italy. The authors have
reported that they have no relationships relevant to the contents of this paper to disclose.Manuscript received February 14, 2011; revised manuscript received July 25, 2011, accepted August 4, 2011.
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1080Even though coronary angiography still represents the gold
standard in the diagnosis of coronary artery disease (CAD),
it has the major limitation that it cannot provide certainty
on the hemodynamic relevance of the observed stenosis.
The measurement of fractional flow reserve (FFR) is a
standardized and well-established method frequently used
in clinical practice to evaluate the hemodynamic significance
of epicardial coronary stenoses identified by coronary an-
giography (1). Achievement of maximal hyperemia is a
key requisite for an accurate calculation of FFR (2). Al-
though intravenous infusion of adenosine is considered
See page 1093
the gold standard (3), its use in the catheterization labora-
tory may have some drawbacks compared with intracoronary
adenosine, such as the need of a large amount of adenosine
and therefore higher costs (4), and a higher occurrence of
systemic adverse effects, in addition to being more time-
consuming. For these reasons, intracoronary currently re-
mains a preferred route of administration of adenosine in
many cardiac catheterization
laboratories. Some studies have
suggested a larger reduction in
FFR by higher doses of adeno-
sine (up to 150 g) (5,6). How-
ever, no study has explored so far
the effects of very high dose of
intracoronary adenosine. There-
fore, the aim of the current study
was to evaluate the effects of
increasing doses of intracoronary
adenosine on FFR.
Methods
Study population. A total of 46 patients with a total of 50
ntermediate coronary stenoses were prospectively enrolled.
xclusion criteria were: 1) allergy to adenosine; 2) baseline
radycardia (heart rate 50 beats/min); 3) hypotension
blood pressure 90 mm Hg); and 4) refusal to provide
igned informed consent. All patients signed the informed
onsent to participate in the study.
Study protocol. Coronary angiography was performed with
the femoral approach. Heart rate and arterial pressure were
continuously monitored throughout the procedure. Heparin
was administered at the beginning of the procedure (60
U/kg), and nonionic contrast material was used for all
patients. After coronary angiography, a 0.014-inch high-
fidelity pressure-recording guidewire (PrimeWire, Volcano,
San Diego, California) was introduced through a 6-F
guiding catheter into the coronary artery. The guidewire
was externally calibrated and then advanced to the distal tip
Abbreviations
and Acronyms
CAD  coronary artery
disease
CVR  coronary flow
velocity reserve
FFR  fractional flow
reserve
QCA  quantitative coronary
angiographyof the catheter, as previously described (7), with the pressuresensor positioned in the coronary artery just out of the
catheter to verify equalization between the pressure recorded
through the catheter and the pressure wire. The pressure
wire was subsequently advanced into the coronary artery
with the pressure sensor placed beyond the lesion site. Distal
coronary and aortic pressures were measured at baseline and
at maximal hyperemia. Pressure signals were continuously
recorded at a paper speed of 25 mm/s, and a beat-to-beat
analysis of mean pressure was performed automatically.
Once a stable pressure signal was obtained, baseline mea-
surements were recorded. In all patients, intracoronary
nitroglycerin (0.2 mg) was administered before coronary
angiography and before each FFR measurement except in
the case of blood pressure 100 mm Hg.
Pharmacological protocol. All patients received multiple
ntracoronary adenosine boluses (60, 120, 180, 360, and 720
g) (Fig. 1). Each bolus was followed by a flush with saline.
Measurement of FFR was started 3 s after bolus adminis-
tration. Each bolus was administrated at least 1 min after
the previous one (in all cases until pressure curves returned
to baseline values). To minimize and standardize fluid
volume infusion, we prepared the drug with a special
dilution of 60 g/ml and 360 g/ml (the last one used for
360 g and 720 g doses).
Calculations of pressure-derived FFR. FFR is defined as the
atio of the hyperemic flow in a stenotic artery to the hyperemic
ow in the same artery in the hypothetical case in which there
s no stenosis present (8). FFR expresses maximum hyperemic
lood flow in a stenotic vessel as a fraction of normal maximal
lood flow in that vessel. FFR is calculated from intracoronary
nd aortic pressure measurements obtained during maximal
yperemia with this equation: FFR  Pd – Pv/Pa  Pv, or
FFR Pd/Pa (when Pv is negligible), in which Pa is the mean
proximal coronary pressure (mean arterial pressure), Pd is the
mean distal coronary pressure, and Pv is the mean central
enous pressure. In this study, the simplified formula (in which
v is considered negligible) was applied.
Figure 1. Study ProtocolFFR  fractional ﬂow reserve; IC  intracoronary; NTG  nitroglycerin.
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1081Coronary angiography and quantitative coronary angiography
analysis. Coronary angiography (carried our by Siemens
xiom ARTIS dTC, Erlangen, Germany) was routinely
erformed by the Judkins technique using 6-F right and left
eart catheters. Quantitative coronary angiography was
erformed by 2 experienced interventional cardiologists who
ad no knowledge of the patients’ clinical information, by
n automatic edge-detection systems (Siemens Acom
uantcor quantitative coronary angiography [QCA]). After
he visual inspection of the coronary artery, the frame of
ptimal clarity was selected, showing the lesion at maximal
arrowing and the arterial silhouette in sharpest focus. After
he calibration of the guiding catheter, the analyzed arterial
egment with the coronary lesion was defined by moving the
ursor from the proximal to the distal part of the coronary
rtery to ensure adequate determination of reference diam-
ter. We have measured minimal luminal diameter, refer-
nce diameter, percent diameter stenosis, and length of the
esion. A stenosis was considered significant if the diameter
Table 1. Baseline Demographic and Clinical Characteristics
in 46 Patients Enrolled in the Study
Demographic characteristics
Male 78.3
Weight, kg 77 (70–85)
Height, cm 170 (165–175)
Body mass index, kg/m2 26 (22–29)
Abdominal waist, cm 95 (90–103)
SBP, mm Hg 131 (110–152)
DBP, mm Hg 69 (59–75)
HR, beats/min 69 (60–78)
Age, yrs 67 (59–73)
Clinical characteristics
Hypertension 82.6
Smoking 28.3
Dyslipidemia 63
Diabetes 26.1
Previous AMI 28.3
Previous PCI 37
Previous CVA 2.2
Creatinine clearance 60 ml/min 15.2
Indication for angiography
Stable angina 15.2
Silent ischemia 6.5
Unstable angina 21.7
NSTEMI 28.3
Recent STEMI 8.7
DCM 13
Values are % or median (25th to 75th percentile).
AMI  acute myocardial infarction; CVA  cerebrovascular accident; DBP  diastolic blood
pressure; DCMdilated cardiomyopathy; HRheart rate; NSTEMInon–ST-segment elevation
myocardial infarction; PCI percutaneous coronary intervention; SBP systolic blood pressure;
STEMI ST-segment elevation myocardial infarction.as more than 70%, and borderline if between 30% and 70%.Statistical analysis. Continuous data are presented as the
edian (25th to 75th percentile), whereas categorical vari-
bles as shown as percentages. The change in the percentage
f patients with significant FFR (0.75) and the absolute
FR values after each incremental intracoronary adenosine
olus were analyzed by the Cochran Q test for repeated
ategorical measures and analysis of variance for repeated
easures (Bonferroni t test was used for paired multiple
omparisons), respectively. Multiple linear regression anal-
sis with a stepwise forward model was used to identify
CA parameters independently associated with FFR. Re-
ults were considered statistically significant when the p
alue was 0.05.
esults
Patient characteristics. Baseline patients’ characteristics and
edical therapy at admission are reported in Tables 1 and 2.
ll patients were in sinus rhythm. In 4 cases (8%), FFR was
erformed in vessels that were in the vascular territory of a
Table 2. Angiographic Characteristics
Number of lesions 50
TIMI ﬂow grade 3 100
Number of diseased vessels
1 44
2 26
3 30
Target vessel FFR
LAD 68
Circumﬂex 14
RCA 12
AL 2
LM 4
QCA target lesion
RD, mm 2.97 (2.57–3.45)
MLD, mm 1.23 (0.9–1.5)
Percent stenosis, % 57 (49–70)
Length, mm 11 (8–19)
Lesion characteristics
Type A 2
Type B1 4
Type B2 86
Type C 8
Lesion location
Proximal 34
Mid 58
Distal 6
Calciﬁcations 16
In-stent restenosis 10
Bifurcation 12.5
Values are % or median (25th to 75th percentile).
AL  anterolateral branch; LAD  left anterior descending artery; LM  left main; MLD 
minimum lumen diameter; QCA  quantitative coronary angiography; RCA  right coronaryartery; RD reference diameter; TIMI Thrombolysis In Myocardial Infarction.
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1082previous infarction. Procedural success was 100% for ad-
vancing the pressure wire distally to the stenosis. There were
no procedure-related complications. Adenosine elicited an
asymptomatic transient atrioventricular block of more than
4 s in 8.7% of patients (3 patients with right coronary artery
stenosis and 1 patient with left circumflex stenosis) (Table 3).
In these cases, the protocol was stopped because of the
inability to correctly measure FFR.
FFR measurements. The mean aortic and distal coronary
ressure and the heart rate were not significantly different
fter each step (Fig. 2). The dose–effect relationship of
denosine in the measurement of FFR is shown in Figure 3.
he mean FFR progressively decreased up to 720 g of
denosine, with a progressive significant increase in the
roportion of patients reaching significant FFR values
0.75) (p 0.001). The cumulative percentage of patients
eaching 0.75 is depicted in Figure 4, showing the highest
ercentage at 720 g (51.2%).
All analyzed QCA parameters, such as lesion length (r 
0.28, p  0.079), percent stenosis (r  0.45, p 
0.003), and minimum lumen diameter (MLD) (r  0.44,
p  0.004) were related with FFR values at 720 g.
However, by multivariate analysis, only percent stenosis
(r  0.53, p  0.001) and lesion length (r  0.38, p 
0.007) were independently related to FFR values at 720 g.
iscussion
This study showed for the first time, to our knowledge, a
dose–effect relationship of intracoronary adenosine (admin-
istrated up to 720 g) in the measurement of FFR.
Furthermore, lesion length, in addition to the severity of the
stenosis, resulted an independent angiographic determi-
nants of FFR.
High-dose intracoronary adenosine: implications for FFR
measurements. CAD is a leading cause of mortality in
eveloped countries. Even though coronary angiography
till represents the gold standard in the diagnosis of CAD,
t has the major limitation of being unable to assess the
emodynamic importance of the observed disease. FFR is a
tandardized and well-established method to detect the
emodynamic importance of intermediate coronary artery
Table 3. Prevalence and Timing of Side Effect Determining Premature
Study Termination
60 g 120 g 180 g 360 g 720 g
RCA 0 0 1 2 0
LAD 0 0 0 0 0
Circumﬂex 0 0 0 1 0
The side effect that terminated the study is defined as complete atrioventricular blockwith pause
longer than 4 s.
LAD left anterior descending artery; RCA right coronary artery.esions and therefore may represent an important comple-ent to coronary angiography. Several advantages have
ontributed to widespread use of FFR, currently the pre-
erred test used in the catheterization laboratory. In fact,
his measure is independent of hemodynamic variation
7,9), and has an ischemic threshold value of 0.75 closely
elated to noninvasive indexes of inducible ischemia (1,10).
ven though intravenous adenosine may achieve a more
omplete and stable vasodilatation and is more convenient
or the assessment of tandem lesions or diffuse CAD, an
ntracoronary bolus is cheaper and more easily adminis-
rated, in addition to having a rapid onset of action and a
Figure 2. Systolic Blood Pressure, Diastolic Blood Pressure, and
Heart Rate at All Steps
This ﬁgure shows systolic blood pressure (A), diastolic blood pressure (B),
and heart rate (C) at all steps from baseline up to 720 g. Values are
median (25th to 75th percentile). NS  not signiﬁcant.
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1083short half-life, which makes it ideal for repetitive measure-
ments. Furthermore, intracoronary administration is asso-
ciated with fewer systemic adverse effects. No major adverse
events related to the intracoronary drug administration have
been reported from multiple large trials measuring FFR
(11). However, submaximal hyperemia may contribute to
underestimatation of the functional severity of the lesion.
According to initial studies, intracoronary adenosine was
administered in a single bolus of 8 to 12 g in the right
oronary artery and 15 to 18 g in the left coronary artery.
However, a failure to produce maximal hyperemia with
intracoronary adenosine was reported in approximately 10%
to 15% of cases (12). A clear dose–response relationship for
intracoronary adenosine doses as high as 100 g has been
demonstrated in animals and humans (5,6,13). Di Segni et
al. (13) observed that incremental doses (54 g for the left
oronary artery and 42 g for the right coronary artery) of
ntracoronary adenosine attained further vasodilatation and
ore accurate coronary flow velocity reserve (CVR) mea-
urements. Similar findings were observed by Murtagh et al.
6) when assessing FFR of intermediate lesions with doses
s high as 48 g. Therefore, at present, larger dosages (30 to
0 g for the right coronary artery and 40 to 80 g for the
left coronary artery) are recommended (14,15). However,
even with these higher doses, Jeremias et al. (12) demon-
strated that intracoronary FFR overestimates intravenous
FFR in 8.3% of patients. Casella et al. (5) compared in 50
patients increasing doses of intracoronary adenosine (up to
150 g) versus intravenous infusion. Despite the high
aseline dose (60 g), 10% of vessels with an initial FFR
alue 0.75 had a subsequent value less than the cutoff
oint when additional higher doses of intracoronary aden-
sine or intravenous adenosine were administered. Despite
Figure 3. FFR at All Steps
This ﬁgure shows the fractional ﬂow reserve (FFR) at all steps from baseline
up to 720 g. Data are reported as median (25th to 75th percentile). *p 
0.001 versus baseline; **p  0.007 versus 120 g; ***p  0.085 versus
360 g.ll previous studies, no investigation has been performed soar to evaluate a dose–effect relationship with very high
oses of adenosine.
In our study, we found a dose–effect relationship of
ntracoronary adenosine (up to 720 g) in the measurement
FR. In fact, FFR significantly decreased from baseline to
0 g, from 120 to 180 g, with an additional increase
p  0.087) from 360 to 720 g of adenosine. We observed
a progressive increase in the number of patients with FFR
0.75 up to 720 g. In agreement with data found by De
Bruyne et al. (16), when we analyzed the impact of QCA
parameters on FFR, we found that both percent stenosis
and lesion length were independently associated with FFR.
This is an important issue that can explain the presence of
ischemia in case of long diseased segments with angio-
graphically judged mild to moderate stenoses.
Study limitations. To remain close to a real clinical scenario,
e enrolled more unselected patients as compared with
revious studies, such as those patients with arterial hyper-
ension, diabetes mellitus, and myocardial infarction, which
re known to be associated with more microvascular dys-
unction. Furthermore, intracoronary adenosine produces a
lateau hyperemic phase of approximately 4 s, which cor-
esponds to 3 to 6 beats, but not to a true steady state. The
bsence of a prolonged hyperemic state is a strong limitation
o FFR measured after intracoronary adenosine administra-
ion, especially in the case of mild to moderate tandem
tenoses or in cases of diffuse disease when a pullback
aneuver of the pressure wire is necessary to detect the
xact location of the critical lesion. In fact, we recognize as
major limitation of our study the fact that we did not
ompare intracoronary adenosine to intravenous adenosine
nfusion (regarded as the gold standard). It would have been
nteresting to escalate the doses of adenosine until FFR
ould not have further decreased in a classical dose-finding
ashion. Therefore, we cannot exclude the possibility that at
oses higher than 720 g, a further decrease in FFR may be
Figure 4. Cumulative Percentage of Patients With FFR <0.75
Bar graph shows the cumulative percentage of patients with fractional ﬂow
reserve (FFR) 0.75 with increasing dose of adenosine.
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1084observed. Finally, although CVR was not measured in this
study, it is reasonable to assume a similar dose–response
relationship on hyperemia for CVR assessment as well.
Conclusions
This study shows that high-dose intracoronary adenosine
(up to 720 g) increased the sensitivity of FFR in the
etection of hemodynamically relevant coronary stenoses.
urthermore, lesion length and stenosis severity were inde-
endent angiographic determinants of FFR.
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